Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

類似資料

• Molecular predictors of response to azacitidine therapy: the results of the UK trials acceleration programme RAVVA study
  著者:: Craddock, C, 等
  出版事項: (2017)
• Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature
  著者:: Craddock, C, 等
  出版事項: (2017)
• Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
  著者:: Craddock, C, 等
  出版事項: (2013)
• Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
  著者:: Craddock, C, 等
  出版事項: (2013)
• INDUCTION OF A CDS+ T CELL RESPONSE TO THE MAGE CANCER TESTIS ANTIGEN BY COMBINED TREATMENT WITH AZACITIDINE AND SODIUM VALPROATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
  著者:: Goodyear, O, 等
  出版事項: (2010)